CoChat

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

Open access
Valsasina, Barbara, Beria, Italo, Alli, Cristina, Alzani, Rachele, Avanzi, Nilla, Ballinari, Dario, Cappella, Paolo, Caruso, Michele, Casolaro, Alessia, Ciavolella, Antonella, Cucchi, Ulisse, De Ponti, Anna, Felder, Eduard, Fiorentini, Francesco, Galvani, Arturo, Gianellini, Laura M., Giorgini, Maria L., Isacchi, Antonella, Lansen, Jaqueline, Pesenti, Enrico, Rizzi, Simona, Rocchetti, Maurizio, Sola, Francesco, Moll, Jürgen · 2012 · Molecular Cancer Therapeutics
Cited by 123

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase considered to be the master player of cell-cycle regulation during mitosis. It is indeed involved in centrosome maturation, bipolar spindle formation, chromosome separation, and cytokinesis. PLK1 is overexpressed in a variety of human tumors and its overexpression often correlates with poor prognosis. Although five different PLKs are described in humans, depletion or inhibition of kinase activity of PLK1 is sufficient to induce cell-cycle arrest and apoptosis in cancer cell lines and in xenograft tumor models. NMS-P937 is a novel, orally available PLK1-specific inhibitor. The compound shows high potency in proliferation assays having low nanomolar activity on a large number of cell lines, both from solid and hematologic tumors. NMS-P937 potently causes a mitotic cell-cycle arrest followed by apoptosis in cancer cell lines and inhibits xenograft tumor growth with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration. In addition, NMS-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing tumor regression in HT29 human colon adenocarcinoma xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of acute myelogenous leukemia in combination with cytarabine. NMS-P937, with its favorable pharmacologic parameters, good oral bioavailability in rodent and nonrodent species, and proven antitumor activity in different preclinical models using a variety of dosing regimens, potentially provides a high degree of flexibility in dosing schedules and warrants investigation in clinical settings. Mol Cancer Ther; 11(4); 1006–16. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-11-0765

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 123

Metadata

Authors
Valsasina, B., Beria, I., Alli, C., Alzani, R., Avanzi, N., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., Cucchi, U., De Ponti, A., Felder, E., Fiorentini, F., Galvani, A., Gianellini, L. M., Giorgini, M. L., Isacchi, A., Lansen, J., Pesenti, E., Rizzi, S., Rocchetti, M., Sola, F., & Moll, J.
Venue
Molecular Cancer Therapeutics
Published
2012-04-01
Volume
11
Issue
4
Pages
1006-1016
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2116068077
Cited by
123
References
2
FWCI
4.57
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. https://app.cochat.ai/papers/10.1158/1535-7163.mct-11-0765
The paper
Valsasina, B., Beria, I., Alli, C., Alzani, R., Avanzi, N., Ballinari, D., Cappella, P., Caruso, M., Casolaro, A., Ciavolella, A., Cucchi, U., De Ponti, A., Felder, E., Fiorentini, F., Galvani, A., Gianellini, L. M., Giorgini, M. L., Isacchi, A., Lansen, J., . . . Moll, J. (2012). NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0765

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.